Kriya Therapeutics announced today that it has raised $80.5 million in a Series A financing to fund the development of transformative gene therapies for highly prevalent serious diseases. Kriya was formed in the fourth quarter of 2019 and has an industry-leading gene therapy team that includes former senior leadership from Spark Therapeutics, AveXis, Sangamo Therapeutics, and other gene therapy companies. Kriya’s pipeline today includes multiple AAV-based gene therapies for the treatment of type 1 and type 2 diabetes, severe obesity, and other indications.
Series A investors include QVT, Dexcel Pharma, Foresite Capital, Bluebird Ventures (associated with Sutter Hill Ventures), Narya Capital, Amplo, Paul Manning, and Asia Alpha. This Series A round follows an initial seed financing completed by the company in the fourth quarter of 2019 led by Transhuman Capital, who also participated in the Series A round.
Kriya is focused on developing gene therapies for diseases affecting millions of patients, expanding the field of gene therapy beyond rare monogenic disorders. Kriya is targeting diseases where the underlying biology is well-understood, with the goal of rationally designing one-time gene therapies to durably express therapeutic proteins within the appropriate human tissues.
Kriya’s initial pipeline includes multiple AAV-based gene therapies for the treatment of metabolic diseases including type 1 diabetes, type 2 diabetes, and severe obesity:
KT-A112 is an investigational gene therapy administered by intramuscular injection that delivers the genes to produce insulin and glucokinase for type 1 and type 2 diabetes.
KT-A522 is an investigational gene therapy administered by salivary gland injection that delivers the gene to produce a glucagon-like peptide 1 (GLP-1) receptor agonist for type 2 diabetes and severe obesity.
KT-A832 is an investigational gene therapy administered by intrapancreatic injection that delivers the gene to produce modified insulin growth factor 1 (IGF-1) for type 1 diabetes.
KT-A112 is an intramuscularly delivered gene therapy for the treatment of Type 1 and Type 2 Diabetes. The approach involves a one-time codelivery of the genetic material to produce insulin and glucokinase, packaged within an AAV vector and delivered directly to skeletal muscle. In the streptozotocin (STZ) induced diabetic mouse model, treated mice exhibited a dose-dependent improvement in glycemic control throughout the observation period. Furthermore, in an induced diabetic dog model, treated dogs followed for up to 8 years demonstrated dramatic and durable improvements in fasting blood glucose, insulinemia, fructosamine (a marker of blood glycosylated proteins), weight, and responsiveness to bolus glucose administration without the need for treatment with exogenous insulin.
KT-A832 is a gene therapy for the treatment of Type 1 Diabetes, designed for direct intrapancreatic delivery. The approach involves a one-time delivery of the genetic material to produce modified insulin growth factor 1 (IGF-1) packaged within an AAV vector to preserve pancreatic beta cell mass in the face of the autoimmune destruction that occurs in Type 1 Diabetes. In the non-obese diabetic (NOD) mouse model, treated mice demonstrated protection against the development of diabetes, together with preservation of pancreatic beta cell mass and insulin production.
Brian Wang is a Futurist Thought Leader and a popular Science blogger with 1 million readers per month. His blog Nextbigfuture.com is ranked #1 Science News Blog. It covers many disruptive technology and trends including Space, Robotics, Artificial Intelligence, Medicine, Anti-aging Biotechnology, and Nanotechnology.
Known for identifying cutting edge technologies, he is currently a Co-Founder of a startup and fundraiser for high potential early-stage companies. He is the Head of Research for Allocations for deep technology investments and an Angel Investor at Space Angels.
A frequent speaker at corporations, he has been a TEDx speaker, a Singularity University speaker and guest at numerous interviews for radio and podcasts. He is open to public speaking and advising engagements.